ImmuVen
Company

Last deal

$1.7M

Amount

Grant

Stage

01.05.2012

Date

3

all rounds

$1.9M

Total amount

General

About Company
ImmuVen develops drugs to treat infectious diseases, cancer, and autoimmune disorders.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

The biotechnology company, ImmuVen, uses a unique technology to discover and develop biotherapeutics that can treat a range of diseases including infectious diseases, cancer, and autoimmune disorders. Their platform enables the rapid selection and optimization of soluble TCR receptors, which are crucial for the development of effective biotherapeutics. ImmuVen is dedicated to improving patient outcomes and addressing unmet medical needs through the development of innovative drugs.
Contacts